Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference

Rhea-AI Summary

Marinus Pharmaceuticals (Nasdaq: MRNS) announced its participation in two major healthcare conferences. Management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 pm EST. Additionally, they will join the H.C. Wainwright Bioconnect 2021 Conference starting January 11, 2021, at 6:00 am EST. Key speakers include CEO Scott Braunstein, CFO Edward Smith, and CMO Joseph Hulihan. Webcasts will be available post-event on the company’s website.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that company management will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. An audio-only presentation will take place January 14, 2021 at 3:40 pm EST. Company management will also participate in the H.C. Wainwright Bioconnect 2021 Conference on January 11.

Additional details can be found below:

H.C. Wainwright Bioconnect 2021 Conference

• Date and Time: On-demand starting Monday, January 11 6:00 am (EST)
• Speakers: Scott Braunstein, M.D., Chief Executive Officer, Edward Smith, Chief Financial Officer, and Joseph Hulihan, M.D., Chief Medical Officer
• Webcast Link: https://journey.ct.events/view/4a598438-edc8-41b3-ba58-04432ebd090b

39th Annual J.P. Morgan Healthcare Conference

• Date and Time: Thursday, January 14 3:40 pm (EST)
• Speakers: Scott Braunstein, M.D., Chief Executive Officer, Edward Smith, Chief Financial Officer, and Joseph Hulihan, M.D., Chief Medical Officer
• Audio Stream Link: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35731-marinus-pharmaceuticals-inc/webcast?gpu_only=true&kiosk=true

Webcast and audio replays will be available following each event under the Investors & Media page of the Company's website at www.marinuspharma.com.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus recently completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder and is conducting a Phase 2 trial in tuberous sclerosis complex, as well as a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company intends to initiate a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005186/en/

FAQ

When will Marinus Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Marinus Pharmaceuticals will present on January 14, 2021, at 3:40 pm EST.

What is the date for the H.C. Wainwright Bioconnect 2021 Conference?

The H.C. Wainwright Bioconnect 2021 Conference starts on January 11, 2021, at 6:00 am EST.

Who will represent Marinus Pharmaceuticals at the upcoming conferences?

Scott Braunstein, Edward Smith, and Joseph Hulihan will represent Marinus Pharmaceuticals.

Where can I find the webcasts for Marinus Pharmaceuticals' presentations?

Webcasts will be available on the Investors & Media page of Marinus Pharmaceuticals' website after each event.

What is the focus of Marinus Pharmaceuticals?

Marinus Pharmaceuticals focuses on developing innovative therapeutics for rare seizure disorders.